Undisclosed in vivo TRAC-CAR T / Azalea Therapeutics - LARVOL DELTA

In vivo TRAC-CAR T cell engineering via cell-selective delivery and genomic locus-specific integration results in immune reset in non-human primates (ACR Convergence 2026) - "This is the first-in-primate demonstration of site-specific gene insertion in primary immune cells in vivo, representing a milestone toward safe, accessible CAR T cell therapies. Our platform achieved potent CD20+ B cell depletion and reset across all tissue compartments following a single injection without lymphodepletion. The depth of depletion and genomic specificity offer efficacy and safety benefits over transient or randomly integrating in vivo platforms."

CAR T-Cell Therapy • IO biomarker • Preclinical • Immunology • CD27